Stem Cells Live: Current and Future Trends in Regenerative Medicine

Challenging opening comments by Greg Bonfiglio to initiate this discussion session with a bang. A series of complications have hit the industry in recent days: failure of the Athersys phase two trial, federal reimbursement for wound healing Apligraf (Organogenesis) cut. The question posed is, ‘where is the industry now and are these events predicative of the future?’ Alain Vertes, Managing …